



Atty. Dkt. No. 080618-0304
Application Serial No.: 10/669,175

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Nicole Zitzmann et al.
Title: USE OF IMINOSUGAR
DERIVATIVES TO INHIBIT
ION CHANNEL ACTIVITY
Appl. No.: 10/669,175
Filing Date: 09/23/2003
Examiner: Unknown
Art Unit: 1614


CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service's "Express Mail Post Office To Addressee" service under 37 C.F.R. § 1.10 on the date indicated below and is addressed to: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

EL 979071345 US January 20, 2004
(Express Mail Label Number) (Date of Deposit)

Suzanne Langley

(Printed Name)


(Signature)

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document, except as noted below, is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The USPTO has waived the requirement under 37 CFR 1.98(a)(2)(i) to submit copies of U.S. patents and U.S. patent application publications when citing and submitting an Information Disclosure Statements in a patent application filed after June 30, 2003 and in an international application that has entered the national stage under 37 USC §371 after June 30, 2003. Accordingly, copies of these types of documents are not being supplied in connection with this application. Reference is being made to Pre-OG Notice from Office of Patent Legal Administration dated July 25, 2003, *Information Disclosure Statements May Be Filed Without Copies of U.S. Patents and Published Applications in Patent Applications filed after June 30, 2003*. However, should the Examiner request any of these documents, Applicants will gladly provide them.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date

1/20/04

By

M. Scott McBride

FOLEY & LARDNER
Customer Number: 22428
Telephone: (414) 297-5529
Facsimile: (414) 297-4900

M. Scott McBride
Attorney for Applicant
Registration No. 52,008



MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: January 20, 2004 <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/669,175
				Filing Date	09/23/2003
				First Named Inventor	Nicole Zitzmann
				Group Art Unit	1614
				Examiner Name	Unknown
				Attorney Docket Number	080618-0304
Sheet	1	of	3		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A1	6,355,413	B1	Gage et al.	03/12/2002	
	A2	6,291,657	B1	Platt et al.	09/18/2001	
	A3	5,622,972		Bryant et al.	04/22/1997	
	A4	5,580,884		Platt et al.	12/03/1996	
	A5	5,310,745		Partis et al.	05/10/1994	
	A6	5,286,877		Behling et al.	02/15/1994	
	A7	5,200,523		Fleet	04/06/1993	
	A8	5,100,797		Fleet et al.	03/31/1992	
	A9	5,043,273		Scudder et al.	08/27/1991	
	A10	5,017,704		Fleet et al.	05/21/1991	
	A11	5,013,842		Fleet et al.	05/07/1991	
	A12	5,011,929		Fleet et al.	04/30/1991	
	A13	4,996,329		Fleet et al.	02/26/1991	
	A14	4,944,572		Young	07/31/1990	
	A15	4,910,310		Campbell et al.	03/20/1990	
	A16	4,894,388		Fleet	01/16/1990	
	A17	4,861,892		Fleet	08/29/1989	
	A18	4,806,650		Schröder et al.	02/21/1989	
	A19	4,405,714		Kinast et al.	09/20/1983	
	A20	4,266,025		Kinast et al.	05/05/1981	
	A21	4,246,345		Kinast et al.	01/20/1981	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A22		WO 01/10429	A2	Zitzmann et al.	02/15/2001		
	A23		WO 99/24401	A1	G.D. Searle & Company	05/20/1999		
	A24		WO 98/35685	A1	Jacob et al.	08/20/1998		
	A25		EP0 455 098	A2	G.D. Searle & Company	02/25/1991		
			445					

Examiner Signature	Date Considered	
--------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Classification). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.



MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: January 20, 2004

(use as many sheets as necessary)

Sheet

2

of

3

Complete if Known

Application Number	10/669,175
Filing Date	09/23/2003
First Named Inventor	Nicole Zitzmann
Group Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	080618-0304


NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A26	BERGERON et al., "Calnexin: a membrane-bound chaperone of the endoplasmic reticulum," TIBS 19 - March 1994, Elsevier Scient Ltd. 0968-0004/94 pp. 124-128.	
	A27	BRANZA-NICHITA et al., "Antiviral of N-Butyldesoxynojirimycin against Bovine Viral Diarrhea Virus Coorelates with Misfolding of E2 Envelope Proteins and Impairment of Their Association into E1-E2 Heterodimers," (2001) J. Virol. 75(8), pp. 3527-36.	
	A28	CARRERE-KREMER et al., "Subcellular Localization and Topology of the p7 Polypeptide of Hepatitis C Virus, (2002) J. Virol. 76(8), pp. 3720-30.	
	A29	CHOUKHI et al., "Involvement of Endoplasmic Reticulum Chaperones in the Folding of Hepatitis C Virus Glycoproteins, (1998) J. Virol., 72(5), pp. 3851-8.	
	A30	COURAGEOT et al., "α-Glucosidase Inhibitors Reduce Dengue Virus Production by Affecting the Initial Steps of Virion Morphogenesis in the Endoplasmic Reticulum," (2000) J. Virol., 74(1): pp. 564-72.	
	A31	DUFF et al., "The Transmembrane Domain of Influenza A M2 Protein Forms Amantadine-Sensitive Proton Channels in Planar Lipid Bilayers," Virology 190, pp. 485-489 (1992) 0042-6822/92 Copyright 1992 by Academic Press, Inc.	
	A32	DURANTEL et al., "Study of the Mechanism of Antiviral Action of Iminosugar Derivatives against Bovine Viral Diarrhea Virus," (2001) J. Virol. 75(19): pp. 8987-98.	
	A33	DWEK, et al., "Targeting Glycosylation as a Therapeutic Approach," Nature Reviews/Drug Discovery, Vol. 1, January 2002, pp. 65-75. Glycobiology Institute, Dept. of Biochemistry, University of Oxford, Oxford OX1 3QU, UK.	
	A34	FISCHER et al., "Amantadine blocks channel activity of the transmembrane segment of the NB protein from influenza B," Eur. Biophys J. (2001) 3-: pp. 416-420, DOI 10.1007/s00240100157.	
	A35	GRIFFIN et al., "The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine," FEBS Letters 535 (2003) pp. 34-38, Elsevier Science B.V. on behalf of the Federation of European Biochemical Societies.	
	A36	HARADA et al., "E2-p7 Region of the Bovine Viral Diarrhea Virus Polyprotein: Processing and Functional Studies," (2000) J. Virol. 74(20): pp. 9498-506.	
	A37	HAY et al., "The molecular basis of the specific anti-influenza action of amantadine," EMBO Journal, Vol. 4 no. 11 pp. 3021-3024, 1985. Oxford, England.	
	A38	LIN et al., "Processing in the Hepatitis C Virus E2-NS2 Region: Identification of p7 and Two Distinct E2-Specific Products with Different C Termini," (1994) J. Virol. 68(8): pp. 5063-73.	
	A39	LOHMANN et al., "Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line," (1999) Science, 285(5424) pp. 110-3.	
	A40	MEHTA et al., "α-Glucosidase inhibitors as potential broad based anti-viral agents," FEBS Lett. 1998 June 23; 430(1-2); pp. 17-22.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.



MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: January 20, 2004 (use as many sheets as necessary)		Complete if Known	
		Application Number	10/669,175
		Filing Date	09/23/2003
		First Named Inventor	Nicole Zitzmann
		Group Art Unit	1614
		Examiner Name	Unknown
		Attorney Docket Number	080618-0304
Sheet	3	of	3

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶	
	A41	MIZUSHIMA et al., "Two Hepatitis C Virus Glycoprotein E2 Products with Different C Termini," (1994) J. Virol. 68(10); pp. 6215-22.		
	A42	MONTAL et al., "Formation of Bimolecular Membranes from Lipid Monolayers and a Study of Their Electrical Properties," Proc. Nat. Acad. Sci. USA 69 (1972) pp. 3561-3566.		
	A43	PAVLOVIC et al., "The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives," PNAS 2003, May 13; 100(10): pp. 6104-8.		
	A44	PETERSON et al., "Transient, Lectin-like Association of Calreticulin with Folding Intermediates of Cellular and Viral Glycoproteins," Molecular Biology of the Cell, Vol. 6, pp. 1173-1184, September 1995 by The American Society for Cell Biology.		
	A45	PIETSCHMANN et al., "Characterization of Cell Lines Carrying Self-Replicating Hepatitis C Virus RNAs," (2001) J. Virol. 75(3); pp. 1252-64.		
	A46	REED et al., "Overview of Hepatitis C Virus Genome Structure, Polyprotein Processing, and Protein Properties," Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, pp. 55-84.		
	A47	SUNSTROM, et al., "Ion Channels Formed by NB, an Influenza B Virus Protein," J. Membrane Biol. 150, pp. 127-132 (1996)		
	A48	WU et al., "Antiviral Effects of an Iminosugar Derivative on Flavivirus Infections," (2002) J. Virol., 76(8): pp. 3596-604.		
	A49	XU et al., "Synthesis of a novel hepatitis C virus protein by ribosomal frameshift," (2001) The EMBO Journal 20(14): pp. 3840-8.		
	A50	ZITZMANN, et al., "Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: Implications for the development of broad spectrum anti-hepatitis virus agents," (2001) Proc. Natl. Acad. Sci. USA, Oct. 12, (21): pp. 11878-82.		

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.